Ignite Creation Date:
2025-12-25 @ 12:03 AM
Ignite Modification Date:
2025-12-25 @ 10:01 PM
Study NCT ID:
NCT01395758
Status:
COMPLETED
Last Update Posted:
2018-04-03
First Post:
2011-07-01
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-07
Start Date Type:
None
Primary Completion Date:
2016-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-08
Completion Date Type:
ACTUAL
First Submit Date:
2011-07-01
First Submit QC Date:
None
Study First Post Date:
2011-07-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-01-31
Results First Submit QC Date:
None
Results First Post Date:
2018-04-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-03-05
Last Update Post Date:
2018-04-03
Last Update Post Date Type:
ACTUAL